Saiful Kabir, M.D.
NPI 1598766321 · Pulmonary Disease Physician · Anderson, IN
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1598766321
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- 01038701A (IN)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
371 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Test to Examine How Well the Lungs Exchange Gases94729 | 98 | $8 |
| Test to Determine Lung Volumes Using Sensors94726 | 97 | $11 |
| Test to Measure Expiratory Airflow and Volume Changes Before and After Medication Administration94060 | 91 | $9 |
| Sleep Study in Sleep Lab With Continuous Airway Pressure (6 Years Or Older)95811 | 45 | $113 |
| Sleep Study Including Heart Rate, Breathing, Airflow, and Effort95806 | 26 | $41 |
| Sleep Study in Sleep Lab (6 Years Or Older)95810 | 14 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 26 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 455 | 90 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 221 | 74 |
| Montelukast Sodium | 200 | 82 |
| Prednisone | 187 | 81 |
| Budesonide/Glycopyr/Formoterolbrand: Breztri Aerosphere | 121 | 24 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 117 | 28 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$442 across 24 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-08-02
- Last updated
- 2017-05-24
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.